ClinicalTrials.gg

Program

Haemophilus influenzae type b

Also written as “Haemophilus influenzae type b- and meningococcal (vaccine)”, “Haemophilus influenzae type b (Conjugate) (Hib)” and “Haemophilus influenzae type b and meningococcal serogroup C (vaccine)”.

Its studies are mostly in Haemophilus Infections · Diphtheria, led by 3 companies.

Furthest: phase 3, since Aug 26, 20058 company-led studies, 1 open or runningNext primary completion: Feb 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline60 open or runningphase 3since Aug 26, 2005Aug 26, 2005none ahead
CanSino Biologics11 open or runningphase 1since Sep 25, 2025Sep 25, 2025Feb 2029phase 1 · NCT07203755
Novartis10 open or runningphase 1since Aug 12, 2008Aug 12, 2008none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 26, 2005First study: phase 3 study in Haemophilus InfectionsNew to GlaxoSmithKlineGlaxoSmithKline · NCT00323050 · 468 enrolled · Spain
  2. Nov 24, 2005Phase 3 study in Haemophilus InfectionsGlaxoSmithKline · NCT00258700 · 478 enrolled · Poland, United Kingdom
  3. Dec 8, 2005Phase 3 study in Haemophilus InfectionsGlaxoSmithKline · NCT00263653 · 297 enrolled · Spain
  4. May 4, 20063 phase 3 studies in Haemophilus InfectionsGlaxoSmithKline · NCT00322335, NCT00326118, NCT00327184
  5. Aug 12, 2008Novartis’s first study: phase 1 study in Haemophilus InfectionsNew to NovartisNovartis · NCT00734565 · 40 enrolled · China
  6. Sep 25, 2025CanSino Biologics’ first study: phase 1 study in DiphtheriaNew to CanSino BiologicsCanSino Biologics · NCT07203755 · 260 planned · China

Ahead

  1. Feb 2029Primary completion: phase 1 study in DiphtheriaCanSino Biologics · NCT07203755

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07203755Diphtheria · China1RecruitingCanSino BiologicsFeb 2029260
NCT00734565Haemophilus Infections · China1CompletedNovartisOct 200840
NCT00327184Haemophilus Infections · Finland, Italy3CompletedGlaxoSmithKlineNov 2006709
NCT00326118Haemophilus Infections · Australia3CompletedGlaxoSmithKlineNov 1, 2007433
NCT00322335Haemophilus Infections · Spain3CompletedGlaxoSmithKlineJul 2006230
NCT00263653Haemophilus Infections · Spain3CompletedGlaxoSmithKlineMar 2005297
NCT00258700Haemophilus Infections · Poland, United Kingdom3CompletedGlaxoSmithKlineJul 2006478
NCT00323050Haemophilus Infections · Spain3CompletedGlaxoSmithKlineMar 2005468

How it is read

Names in the registry

  • “Haemophilus influenzae type b- and meningococcal (vaccine)”, 4 entries
  • “Haemophilus influenzae type b (Conjugate) (Hib)”, 1 entry
  • “Haemophilus influenzae type b and meningococcal serogroup C (vaccine)”, 1 entry
  • “Haemophilus influenzae type b- and meningococcal serogroup C (vaccine)”, 1 entry
  • “Haemophilus influenzae type b”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.